InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Rare Disease Clinical Trials Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune and Inflammation, Hematologic Disorders, Musculoskeletal Disorders), Phase (Phase I, II, III, and IV), And Sponsor (Pharmaceutical & Biopharmaceutical Companies, Non-profit Organizations)- Market Outlook And Industry Analysis 2031”
The global Rare Disease Clinical Trials market is estimated to reach over USD 25.05 billion by 2031, exhibiting a CAGR of 9.39% during the forecast period.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1690
The global suspension of elective treatments, including diagnostic and therapeutic procedures, due to the COVID-19 pandemic had a significant impact on the market for rare disease treatments. A review published in the Frontiers in Public Health journal in April 2021 highlighted the challenges faced by individuals with rare disorders, concluding that regular clinical care, counseling, and therapies were insufficient during the pandemic.
Additionally, factors such as increased research and development activities for novel therapeutics and drugs, a rise in the number of new drug launches, the growing prevalence of rare diseases, supportive vaccination initiatives, and favorable government policies are all contributing to the ongoing expansion of the market.
List of Prominent Players in the Rare Disease Clinical Trials Market:
- Takeda Pharmaceutical Company;
- Hoffmann-La Roche Ltd.;
- Pfizer, Inc.;
- AstraZeneca;
- Novartis AG;
- LabCorp;
- IQVIA, Inc.;
- Charles River Laboratories;
- Icon PLC;
- Parexel International Corporation
Market Dynamics:
Drivers-
The market for rare disease treatments is expanding due to several key factors, including advancements in treatment innovation, increasing product approvals, and strategic collaborations and acquisitions by major companies. For example, the European Medicines Agency (EMA) approved Xenpozyme (olipudase alfa) in May 2022 for the treatment of non-central nervous system (CNS) aspects of Acid Sphingomyelinase Deficiency (ASMD), a rare and progressive genetic disorder.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/1690
Challenges:
A significant challenge in the clinical trials for rare diseases is the need for multicenter, often international, studies to ensure sufficient patient recruitment, particularly in phases I and II. This requirement can complicate the coordination of procedures, ethical reviews, indemnity agreements, clinical service organization, and cultural diversity considerations.
Regional Trends:
North America is expected to maintain a dominant share of the global rare disease treatments market, driven by the high prevalence of rare diseases such as Huntington’s disease, spina bifida, fragile X syndrome, Guillain-Barré syndrome, Crohn’s disease, cystic fibrosis, and Duchenne muscular dystrophy. The region benefits from heightened awareness of these diseases and a robust healthcare system capable of diagnosing and treating rare conditions.
According to the Genetic and Rare Diseases (GARD) Information Center, approximately 7,000 rare diseases are identified, with one in ten Americans—about 30 million people—affected by one. Similarly, the Canadian Organization for Rare Disorders (CORD) reported in 2021 that one in twelve Canadians is impacted by a rare disease annually, with genetic mutations responsible for 80% of these cases. As a result, the market in North America is poised for substantial growth in the coming years.
Recent Developments:
- In January 2023, Genethon, an R&D company, began a crucial clinical trial for the use of gene therapy to treat Crigler-Najjar Syndrome. Crigler-Najjar syndrome is a rare genetic liver disease marked by abnormally elevated bilirubin levels in the blood. (hyperbilirubinemia).
- In November 2022, The Biologics License Application (BLA) for PRX-102 (pegunigalsidasealfa) for the treatment of adult patients with Fabry disease was re-submitted to the US Food and Drug Administration (FDA) by ProtalixBiotherapeutics Inc. and Chiesi Global Rare Diseases.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1690
Segmentation of Rare Disease Clinical Trials Market-
By Therapeutic area-
- Oncology
- Cardiovascular Disorders
- Neurological Disorders
- Infectious Disease
- Genetic Disorders
- Autoimmune and Inflammation
- Hematologic Disorders
- Musculoskeletal Disorders
- Others
By Phase-
- Phase I
- Phase II
- Phase III
- Phase IV
By Sponsor-
- Pharmaceutical & Biopharmaceutical Companies
- Non-profit Organizations
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More information: @
https://www.insightaceanalytic.com/report/rare-disease-clinical-trials-market/1690
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
